In this engaging podcast, Drs. Bradley Monk and Robert Burger discuss important practical issues regarding the use of antiangiogenic therapy to treat epithelial ovarian cancer, including the possible value of targeted agents as maintenance therapy, the correct dosage and duration of targeted therapy, and the role of CA125 in determining tumor progression with a biologic agent
Show More
Creators & Guests
We don't know anything about the creators of this podcast yet. You can so they can be credited for this and other podcasts.